Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

5 terminated/withdrawn out of 20 trials

Success Rate

70.6%

-15.9% vs industry average

Late-Stage Pipeline

30%

6 trials in Phase 3/4

Results Transparency

92%

11 of 12 completed trials have results

Key Signals

11 with results

Enrollment Performance

Analytics

Phase 2

9(47.4%)

Phase 3

6(31.6%)

Phase 1

4(21.1%)

19Total

Phase 2(9)

Phase 3(6)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT05954286Phase 2Completed

PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19

Role: collaborator

NCT04467840Phase 2Completed

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

Role: lead

NCT03377179Phase 2Completed

A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma

Role: lead

NCT03414489Unknown

Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)

Role: lead

NCT04616924Phase 3Terminated

RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease

Role: lead

NCT04723537Phase 2Terminated

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

Role: lead

NCT04026984Phase 2Unknown

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Role: lead

NCT04027894Phase 2Unknown

Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years

Role: lead

NCT04414618Phase 2Completed

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Role: lead

NCT02757326Phase 1Terminated

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

Role: lead

NCT03009396Phase 3Completed

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease

Role: lead

NCT01951326Phase 3Completed

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

Role: lead

NCT04502069Phase 1Withdrawn

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

Role: lead

NCT03198507Phase 3Completed

ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator

Role: lead

NCT01488513Phase 1Completed

ABC294640 in Treating Patients With Advanced Solid Tumors

Role: lead

NCT01980095Phase 3Completed

ERADICATE Hp - Treating Helicobacter Pylori With RHB-105

Role: lead

NCT02246439Phase 3Completed

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis

Role: lead

NCT02757105Phase 2Completed

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

Role: lead

NCT02229981Phase 1Withdrawn

Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma

Role: lead

NCT01717664Phase 2Completed

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)

Role: lead

All 20 trials loaded